A global coalition of more than 50 infectious disease experts is warning of a “silent surge” in antifungal resistance, urging health authorities to treat the rise of drug-resistant fungi as a critical component of the broader fight against antimicrobial resistance (AMR).
In a call to action published in Nature Medicine, researchers argue that global health strategies have focused overwhelmingly on bacterial and viral threats, leaving a dangerous gap in the surveillance and treatment of fungal pathogens. This oversight, they contend, is already costing lives in intensive care units and community settings worldwide.
The group, led by Paul Verweij of the Radboud University Medical Centre in the Netherlands, is pushing for a fundamental shift in how the World Health Organization (WHO) approaches the crisis. Their goal is to ensure that fungal resistance is formally integrated into the upcoming update of the Global Action Plan on AMR, which was first established a decade ago.
“We are facing a silent surge of drug‑resistant fungi – from Candida auris in [intensive care units] to azole‑resistant Aspergillus in the community – that is already costing lives,” Verweij stated.
The clinical toll of invasive fungal diseases
Fungal infections are often overlooked due to the fact that they primarily target the most vulnerable. However, the scale of the problem is significant: invasive fungal diseases affect more than 6.5 million people annually. Even when these pathogens are susceptible to current medications, mortality rates remain high; when resistance enters the equation, the prognosis worsens sharply.
Two pathogens are of particular concern to the medical community. Candida auris, a multidrug-resistant yeast, has emerged as a formidable threat in healthcare settings. It frequently causes severe bloodstream infections in patients with compromised immunity and researchers note that roughly one in three patients who contract the infection do not survive.
Simultaneously, Aspergillus fumigatus—a common mold found in the environment—is becoming increasingly difficult to treat. This inhaled infection is appearing more frequently in intensive care units, particularly among patients suffering from severe influenza, as the fungi develop resistance to azoles, a primary class of antifungal drugs.
From the farm to the ICU
One of the most concerning aspects of this surge is that it does not initiate in the hospital. Professor Michaela Lackner of the Medical University of Innsbruck in Austria points to a dangerous synergy between medicine and industry. Many of the antifungal agents used to treat human patients are chemically similar to the fungicides used in large-scale agriculture to protect crops.
This dual use creates an environmental breeding ground for resistance. Fungi exposed to agricultural fungicides in the soil and air can develop mutations that make them resistant to the same drugs used in clinical settings. This process, Lackner notes, is “accelerating resistance from fields to ICU,” meaning patients may arrive at the hospital already carrying strains that the current medical arsenal cannot kill.
A stagnant pharmaceutical pipeline
The crisis is compounded by a lack of innovation. For decades, the pharmaceutical industry has largely retreated from the development of new anti-infectives, which are often less profitable than chronic-disease medications. Since the WHO first drew up its action plan in 2015, only a handful of new antifungal agents have reached the market.
| Medication | Developer | Year Approved |
|---|---|---|
| Brexafemme (ibrexafungerp) | GSK/Scynexis | 2021 |
| Vivjoa (oteseconazole) | Mycovia Pharma | 2022 |
| Rezzayo (rezafungin) | Cidara/Melinta | 2023 |
While these approvals provide new tools for clinicians, the experts argue they are not enough to maintain pace with the evolving nature of fungal resistance.
The five-step roadmap for global action
To prevent a repeat of the mistakes made during the early years of antibacterial resistance, the researchers have proposed a comprehensive five-step plan. They are calling for the 2026 Global Action Plan on AMR to include concrete milestones and dedicated funding for the following:
- Raising Awareness: Educating healthcare providers and the public on the risks of fungal infections.
- Improved Surveillance: Implementing better tracking systems to identify emerging resistant strains in real-time.
- Infection Prevention: Strengthening hygiene and control protocols in hospitals to stop the spread of pathogens like C. Auris.
- Optimized Therapy: Implementing strict antifungal stewardship to ensure current drugs are used correctly and not overused.
- Investment in Innovation: Ramping up funding for new diagnostics and medicines, with a specific focus on technology transfer and local manufacturing in low- and middle-income countries.
The authors emphasize that this approach must be “One Health” in nature, meaning it must integrate clinical medicine, agricultural policy, and environmental protection to stop resistance at its source.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next critical milestone will be the formal update of the WHO’s Global Action Plan on AMR, expected later this year and extending into 2026. Whether the international community will allocate the necessary funding and policy shifts to address the fungal threat remains to be seen.
Do you think global health priorities are shifting fast enough to meet these “silent” threats? Share your thoughts in the comments or share this story with your network.
